David Jensen reports on the future of CIRM as a “beautiful machine”. CIRM funds brain cancer research in a big way: Funding a clinical trial for deadly cancer is a no brainer. Glioblastoma is a fatal tumor that needs new clinical approaches so this is exciting. One of the goals of my lab is to find new pathways to treat glioblastoma in children. Jacob Corn of IGI has a Wish List for Science on CRISPR science, but also science more generally. The case for possibly retracting a retraction …Read More
With more than 250 votes cast, Jennifer Doudna is leading by a decisive margin in a poll asking who deserves the patent for use of CRISPR-Cas9 as a tool. Feng Zhang got only just over half the votes of Doudna. Another take home message from this poll is that a sizable minority–almost one in five– said neither should have a patent on this technology. Geographically the results were fairly consistent across countries, but notably in the UK the top response was, “Neither”. This poll is …Read More
There is no hotter technology than CRISPR-Cas9 gene editing tools. Perhaps it is not surprising then that there is a patent dispute over it, which falls into two camps: (1) Jennifer Doudna & Emmanuelle Charpentier, and (2) Feng Zhang. Who deserves the intellectual property for use of CRISPR-Cas9 in human cells? Take our poll.
CRISPR Cas9 is a relatively new, powerful approach to gene editing and genetic modification more generally. In the relatively short window of time in which this technology has been widely available for gene editing applications it has already evolved rapidly to become more powerful. Here are some new papers of interest on this technology. With many CRISPR papers every week these days there are probably other great papers too. What are your favorite recent papers in this area lately? How much off-site targeting is …Read More